23-epi-26-Deoxyactein
(Synonyms: 脱氧升麻烃,27-Deoxyactein) 目录号 : GC42091
A triterpene glycoside
Cas No.:264624-38-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
23-epi-26-Deoxyactein is a triterpene glycoside and a major constituent of black cohosh (C. racemosa). It reduces intracellular calcium concentrations, collapse of the mitochondrial membrane potential, production of reactive oxygen species (ROS), and cardiolipin peroxidation and inhibits autophagy and apoptosis in osteoblastic MC3T3-E1 cells induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). 23-epi-26-Deoxyactein (0.01-10 μM) reduces production of ROS and IL-1β and cell death induced by methylglyoxal in RIN-m5F β-cells.
| Cas No. | 264624-38-6 | SDF | |
| 别名 | 脱氧升麻烃,27-Deoxyactein | ||
| Canonical SMILES | C[C@](CO1)(O2)[C@@H]2[C@@]31O[C@@]4([H])C[C@@]5(C)[C@]6([H])CC[C@]7([H])[C@]8(CC[C@H](O[C@]9([H])OC[C@@H](O)[C@H](O)[C@H]9O)C7(C)C)[C@]6(C8)C[C@@H](OC(C)=O)[C@]5(C)[C@@]4([H])[C@H](C)C3 | ||
| 分子式 | C37H56O10 | 分子量 | 660.8 |
| 溶解度 | Water: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5133 mL | 7.5666 mL | 15.1332 mL |
| 5 mM | 0.3027 mL | 1.5133 mL | 3.0266 mL |
| 10 mM | 0.1513 mL | 0.7567 mL | 1.5133 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Effects of 23-epi-26-Deoxyactein on adipogenesis in 3T3-L1 preadipocytes and diet-induced obesity in C57BL/6 mice
Phytomedicine 2020 Jun 5;76:153264.PMID:32570112DOI:10.1016/j.phymed.2020.153264.
Background: The ethanolic extract of Actaea racemosa L. (Cimicifuga racemosa (L.) Nutt.) has recently been reported to ameliorate obesity-related insulin resistance, hyperlipidemia, and fatty liver in rodents. However, it remains unclear which A. racemosa components are responsible for these beneficial effects. Purpose: We aimed to examine the anti-obesity potential of 23-epi-26-Deoxyactein (DA), which is contained in the ethanolic extracts of A. racemosa. Study design and methods: To evaluate the effects of DA on adipogenesis in 3T3-L1 preadipocytes and diet-induced obesity in C57BL/6 mice, in vitro and in vivo tests were performed. For in vitro assessment, we used Oil red O staining that showed lipid accumulation in differentiated 3T3-L1 cells. For in vivo tests, male 5-week-old C57BL/6 mice were fed with low-fat diet (LFD), high-fat diet (HFD), HFD with 10 mg/kg/d luteolin (LU; positive control drug), HFD with 1 mg/kg/d DA, and HFD with 5 mg/kg/d DA for 12 weeks, respectively. Glucose and insulin tolerance tests were performed at week 17. The lipid deposition of adipose tissue and liver was visualized by hematoxylin and eosin staining. Real-time PCR showed mRNA levels of genes involved in adipogenesis, lipogenesis, and lipolysis. AMPK signaling and SIRT1-FOXO1 pathway were assessed by real-time PCR and western blot. Results: 10 μM DA and 20 μM LU treatments inhibited 3T3-L1 adipogenesis through down-regulating the expression of C/ebpα, C/ebpβ, and Pparγ, which are the critical adipogenic transcription factors. The in vivo results showed that 5 mg/kg/d DA and 10 mg/kg/d LU significantly lowered body weight gain, fat mass, and liver weight in HFD-fed mice. Meanwhile, DA and LU also reduced insulin resistance and serum lipoprotein levels in HFD-fed mice. Mechanistic studies showed that DA and LU promoted adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway. Conclusion: The in vitro results indicate that 10 μM DA suppresses adipogenesis in 3T3-L1 preadipocytes. The in vivo treatment with 5 mg/kg/d DA ameliorates diet-induced obesity in mice, suggesting that DA is a promising natural compound for the treatment of obesity and related metabolic diseases.
Pharmacokinetics of 23-epi-26-Deoxyactein in women after oral administration of a standardized extract of black cohosh
Clin Pharmacol Ther 2010 Feb;87(2):219-25.PMID:20032972DOI:10.1038/clpt.2009.251.
Dietary supplements containing black cohosh are alternatives to conventional hormone replacement therapy in menopause. This study investigates the maximum tolerated dose of a 75% ethanol extract of black cohosh and determines the pharmacokinetics of one of its most abundant triterpene glycosides, 23-epi-26-Deoxyactein. Single doses of black cohosh extract containing 1.4, 2.8, or 5.6 mg of 23-epi-26-Deoxyactein were administered to 15 healthy, menopausal women. Serial blood samples and 24-h urine samples were obtained; blood chemistry, hormonal levels, and 23-epi-26-Deoxyactein levels were determined. No acute toxicity or estrogenic hormone effects were observed. Pharmacokinetic analyses of 23-epi-26-Deoxyactein in sera indicated that the maximum concentration and area under the curve increased proportionately with dosage, and that the half-life was ~2 h for all dosages. Less than 0.01% of the 23-epi-26-Deoxyactein was recovered in urine 24 h after administration. No phase I or phase II metabolites were observed either in clinical specimens or in vitro.
Simultaneous determination of cimicifugoside H-2, cimicifugoside H-1, 23-epi-26-Deoxyactein, cimigenol xyloside and 25-O-acetylcimigenoside in beagle dog plasma by LC-MS/MS
J Pharm Biomed Anal 2012 Mar 25;62:87-95.PMID:22285707DOI:10.1016/j.jpba.2011.11.029.
A selective and sensitive LC-MS/MS method was developed and validated for the simultaneous determination of five constituents (cimicifugoside H-2, cimicifugoside H-1, 23-epi-26-Deoxyactein, cimigenol xyloside and 25-O-acetylcimigenoside) of Cimicifuga foetida L. in beagle dog plasma. The quantitation was performed on a LC-MS/MS with negative electrospray ionization in selected reaction monitoring (SRM) mode. A gradient mobile phase composed of methanol and water was used at a flow rate of 0.4 ml/min. All the analytes and internal standard (20 (S)-ginsenoside Rg3) were isolated from plasma samples by a liquid-liquid extraction method. The average extraction recoveries were 73-74% for cimicifugoside H-2, 89-94% for cimicifugoside H-1, 73-80% for 23-epi-26-Deoxyactein, 89-91% for cimigenol xyloside, 87-96% for 25-O-acetylcimigenoside, respectively. The method showed good linearity and no endogenous material interfered with all the five compounds and I.S. peaks. The lower limit of quantification (LLOQ) of all analytes was 0.5 ng/ml. The intra- and inter-day precision of analysis was less than 15% for each analyte at concentrations of 2.0, 50, 500 ng/ml, and the accuracy ranged from 85.8% to 107%. This method was successfully applied to reveal the pharmacokinetic properties of cimicifugoside H-2, cimicifugoside H-1, 23-epi-26-Deoxyactein, cimigenol xyloside and 25-O-acetylcimigenoside after oral administration.
LC/TIS-MS fingerprint profiling of Cimicifuga species and analysis of 23-epi-26-Deoxyactein in Cimicifuga racemosa commercial products
J Agric Food Chem 2005 Mar 9;53(5):1379-86.PMID:15740010DOI:10.1021/jf048300d.
In this study, a liquid chromatography (LC)/turbo ion spray (TIS)-mass spectrometry (MS) method was developed to examine the chromatography or "fingerprint profile" of seven Cimicifuga herbs and six Cimicifuga racemosa (black cohosh) commercial products. Triterpene glycoside components were selected as chemical markers for analysis because they have appeared as a major compound group in Cimicifuga species. LC/MS chromatograms unveiled the patterns of C. racemosa, Cimicifuga dahurica, Cimicifuga foetida, Cimicifuga heracleifolia, Cimicifuga japonica, Cimicifuga acerina, and Cimicifuga simplex, which are very different from each other. 23-epi-26-Deoxyactein was found only in C. racemosa, C. dahurica, and C. foetida. A highly selective and sensitive LC/MS/MS method for quantitative analysis of 23-epi-26-Deoxyactein with detection levels up to 2.5 ng in these samples was also developed and was applied to six commercial C. racemosa products. C. racemosa and its six commercial products contained about 6-15% of 23-epi-26-Deoxyactein in total triterpene glycosides. On the other hand, the estimated amount of total triterpene glycosides in other commercial products was either greater or lesser than what the manufacturers claimed. The technique and LC/MS profiles generated in this study provide a reliable and reproducible method that can be readily utilized for botanical identification of Cimicifuga plants, for examination and validation of its commercial products, and for "chemical" quality control in the manufacture of black cohosh products.
Isolation, structure elucidation, and absolute configuration of 26-deoxyactein from Cimicifuga racemosa and clarification of nomenclature associated with 27-deoxyactein
J Nat Prod 2002 Apr;65(4):601-5.PMID:11975513DOI:10.1021/np010494t.
A new triterpene glycoside, 26-deoxyactein (1), along with two known compounds, 23-epi-26-Deoxyactein (2), previously designated as "27-deoxyactein", and actein (3), were isolated from the roots/rhizomes of Cimicifuga racemosa. The structures and absolute stereochemistry of 1 and 2 were established by spectroscopic methods (FABMS, (1)H and (13)C NMR) and single-crystal X-ray data analysis.